Navigation Links
Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
Date:11/12/2008

Left untreated, urea cycle disorders can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.

About HPN-100

HPN-100 is a pro-drug of phenylbutyrate and a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle deficiencies including those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100, which is dosed orally in liquid form, provides an alternative pathway to the urea cycle for the disposal of waste nitrogen through the renal excretion of phenylacetylglutamine, which is formed from phenylacetic acid and glutamine.

About BUPHENYL(R)

BUPHENYL(R) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). BUPHENYL(R) should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation. The most common adverse reactions associated with BUPHENYL(R) were amenorrhea dysfunction, decreased appetite, body odor (probably caused by its metabolite phenylacetate) and bad taste or taste aversion. Patients with urea cycle disorders should not take valproic acid, haloperidol, or steroids as these drugs have been reported to increase blood ammonia levels, and probenecid may affect the kidneys' excretion. Use with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states where there is sodium retention with edema. Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. The safety or efficacy of doses in excess of 20 gra
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
2. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
3. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
4. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
5. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
6. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
7. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
8. Cornerstone Therapeutics Announces New Board of Directors
9. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
10. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
11. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... , ... According to WFLA on July 16th, Sarasota has seen ... overdoses. Thricefold deaths have held steady over the last “couple of months” according to ... which was spurred by the crackdown of prescription painkillers. Many users who were addicted ...
(Date:7/31/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... of Midwives delivered the 100th baby at Beaumont Hospital's Karmanos Center for ... home-like environment for expectant mothers looking for a safe natural childbirth experience. With ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce that ... in a mobile application format available on iPhones, iPads, and Android smartphones and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... are 100% organic, natural, therapeutic-grade oils from ingredients sourced all over the world, ... that “With considerable effort, we have developed the highest-quality oils in the industry, ...
(Date:7/31/2015)... Baltimore, MD (PRWEB) , ... July 31, 2015 ... ... Lure Docs of All Types " from NBC talked about a woman’s unfortunate ... dermatology. He performed sclerotherapy on her face, which resulted in blistering, swelling, bruising, ...
Breaking Medicine News(10 mins):Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3
... , , , ... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products ... 4, 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , ... the quarter was $19.8 million, or 17.0% higher than the second quarter ...
... , , Results , , ... Corporation (Nasdaq: DRRX ) announced today financial results for the ... the three months ended June 30, 2009, compared to $6.3 million for ... ended June 30, 2009 was $7.5 million, compared to a net loss ...
... , , BIRMINGHAM, Ala., Aug. 3 ... reports Operating Income of $50.4 million, or $1.52 per diluted share for ... million, or $1.62 per diluted share. For the six months ended June ... and Net Income was $82.2 million, or $2.46 per diluted share. , ...
... activities, such as painting, study finds , MONDAY, Aug. ... time in front of the television, the computer and video ... a new study suggests. , American and Spanish researchers examined ... boys and girls, 3 to 8 years old. For seven ...
... An international ... may lead to new areas for drug development in melanoma - a cancer that is ... ... identified a new method for selectively killing metastatic melanoma cells, which may lead to new ...
... , NATICK, Mass., Aug. 3 Boston ... participate in the BMO Capital Markets 9(th) Annual Focus on ... Ray Elliott, President and Chief Executive Officer, will make a ... a.m. E.T. Following the presentation, Sam Leno, Executive Vice ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Results 2Health News:ATS Medical Announces Second Quarter 2009 Results 3Health News:ATS Medical Announces Second Quarter 2009 Results 4Health News:ATS Medical Announces Second Quarter 2009 Results 5Health News:ATS Medical Announces Second Quarter 2009 Results 6Health News:ATS Medical Announces Second Quarter 2009 Results 7Health News:ATS Medical Announces Second Quarter 2009 Results 8Health News:ATS Medical Announces Second Quarter 2009 Results 9Health News:ATS Medical Announces Second Quarter 2009 Results 10Health News:ATS Medical Announces Second Quarter 2009 Results 11Health News:DURECT Corporation Announces Second Quarter 2009 Financial 2Health News:DURECT Corporation Announces Second Quarter 2009 Financial 3Health News:DURECT Corporation Announces Second Quarter 2009 Financial 4Health News:DURECT Corporation Announces Second Quarter 2009 Financial 5Health News:DURECT Corporation Announces Second Quarter 2009 Financial 6Health News:DURECT Corporation Announces Second Quarter 2009 Financial 7Health News:DURECT Corporation Announces Second Quarter 2009 Financial 8Health News:DURECT Corporation Announces Second Quarter 2009 Financial 9Health News:ProAssurance Reports Second Quarter 2009 Results 2Health News:ProAssurance Reports Second Quarter 2009 Results 3Health News:ProAssurance Reports Second Quarter 2009 Results 4Health News:ProAssurance Reports Second Quarter 2009 Results 5Health News:ProAssurance Reports Second Quarter 2009 Results 6Health News:ProAssurance Reports Second Quarter 2009 Results 7Health News:ProAssurance Reports Second Quarter 2009 Results 8Health News:ProAssurance Reports Second Quarter 2009 Results 9Health News:ProAssurance Reports Second Quarter 2009 Results 10Health News:ProAssurance Reports Second Quarter 2009 Results 11Health News:ProAssurance Reports Second Quarter 2009 Results 12Health News:ProAssurance Reports Second Quarter 2009 Results 13Health News:Young Kids' Screen Time May Raise Blood Pressure 2Health News:Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells 2Health News:Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells 3
(Date:7/31/2015)... -- The Physician-Patient Alliance for Health & Safety ... "Surviving Your Hospital Stay: Physician-Patient Alliance for Health ... A sentence was omitted from the release. ... is a member of the National Coalition to Promote ... the National Coalition to Promote Continuous Monitoring of Patients ...
(Date:7/31/2015)... July 31, 2015 According to a ... (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services ... (Hospitals, Pharmaceuticals) - Global Forecast to 2020", published by MarketsandMarkets, ... 6.1 Billion by 2020, at a CAGR of 7.6%.from 2015 ... market data T ables and 37 ...
(Date:7/31/2015)... , July 31, 2015 Quietly, ... of experience, the domestic pharmaceutical industry is strong, with ... products to high international standards. One place ... is in sub-Saharan Africa: Morocco has quietly become the ... South Africa . Indeed, Moroccan pharma companies ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... Jan. 21, 2011 Matrixx Initiatives, Inc. (Nasdaq: ... healthcare company that develops and markets Zicam® products, today ... by the Agreement and Plan of Merger, dated as ... Holdings, Inc. ("Wonder") and Wonder Holdings Acquisition Corp. (the ...
... Ariz., Jan. 20, 2011 Matrixx Initiatives, Inc. (Nasdaq: ... markets Zicam® products, today announced financial results for its fiscal ... For the third quarter ended December 31, 2010, ... below the $28.5 million in net sales for the comparable ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 2Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 3Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 4Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 5Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share 2Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share 3Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share 4Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share 5
The ACP 215 is the automated closed system cell processor with integrated process control....
... Blood collection centers throughout the world are ... improve the safety of the blood supply ... a constantly shrinking donor base. Clearly, these ... self-sufficient, to better manage their existing donor ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
Medicine Products: